AllAnalyst Report
logoMorningstarSeptember 08, 2020

Alcon Inc.: Alcon Has Likely Faced the Worst of the Pandemic's Effects, but Full Recovery Far From Certain

Symbols
ALC
Sector(s)
Healthcare
Rating
Current Price
$68.49
Fair Value
Economic Moat
Stewardship
Summary

Alcon, headquartered in Fort Worth, Texas, is the global eye care leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Aaron Degagne

Equity Analyst
Aaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.